FOX Family in Triple-Negative Breast Cancer
How FOXA1 loss and FOXM1 activation shape subtype identity, stemness, metastasis, and treatment resistance in TNBC
FOXA1 loss and FOXM1 activation shape different parts of triple-negative breast cancer biology.
FOXA1 helps define subtype identity and restrains stress-tolerance and stemness programs, while FOXM1 drives proliferation, EMT, metastasis, stemness, and treatment resistance.
At a glance
FOXM1 carries major oncogenic weight in TNBC. It drives cell-cycle progression, EMT, invasion, angiogenesis, stemness, metastasis, autophagy, and chemotherapy resistance.
FOXA1 has a context-dependent role in TNBC. In most TNBCs it is low, and loss of FOXA1 removes suppression of SOD2 and IL6, increasing stress tolerance, stem-like behavior, migration, and aggressiveness.
AR+/FOXA1+ TNBC is a distinct luminal-like TNBC subgroup. It is associated with worse recurrence-free and overall survival, higher risk of late recurrence, and enrichment for PIK3CA mutations.
FOXM1 is the stronger practical intervention node. It sits upstream of cyclins, mitotic regulators, EMT programs, MMPs, VEGF, PDGF/Akt signaling, and stem-cell maintenance.
Honokiol and andrographolide remain relevant in TNBC for different reasons. Honokiol directly antagonizes FOXM1 and also suppresses NF-kB, Akt, EGFR/c-Src, and mTOR-linked survival pathways. In ER-positive disease it also weakens ER-linked survival circuitry, giving dual FOXM1/ER-relevant action across subtypes. Andrographolide suppresses FOXM1-driven ER biology in ER-positive disease and reduces TNBC cancer stem-cell properties via NF-kB/THOC1 and apoptosis-linked programs.
This is not a bone-only story. FOXA1 and FOXM1 influence the upstream programs needed for lung, liver, brain, and bone spread, including EMT, invasion, stemness, survival under stress, and outgrowth after therapy.
Contents
1. FOXA1 — lineage gatekeeper and suppressive brake in TNBC
Normal pattern in TNBC
FOXA1 is best understood in TNBC as a context marker and suppressive brake rather than a uniformly activated oncogene.
FOXA1 expression is markedly lower in TNBC than in luminal tumors. One immunohistochemistry cohort found low FOXA1 expression in 82.72% of TNBCs, while high FOXA1 expression was more characteristic of luminal cancers.
This low-FOXA1 state carries biologic weight rather than serving as a passive subtype label.
In TNBC models, FOXA1 knockdown reduced apoptosis, accelerated proliferation, increased migration, and increased the proportion of stem-like cells. This shows that FOXA1 loss removes a restraint on aggressive behavior.
FOXA1 and what it suppresses
FOXA1 directly suppresses SOD2 and IL6 at the promoter level in TNBC models.
These are important downstream effectors. SOD2 helps tumor cells buffer oxidative stress and avoid apoptosis. IL6 supports mammosphere formation, stemness, and invasive transition.
In practical terms, low FOXA1 opens a two-part aggressive program in TNBC: stronger survival under stress and stronger stem-like, invasive behavior.
This gives FOXA1 real mechanistic weight in TNBC even when the issue is loss of control rather than classical oncogenic activation.
2. AR+/FOXA1+ luminal-like TNBC subgroup
Most TNBCs are FOXA1-low, but AR+/FOXA1+ tumors form a distinct luminal-like subgroup.
In this setting, FOXA1 helps AR bind chromatin and directs AR toward a luminal-like transcriptional program that supports proliferation and subtype-specific signaling.
This subgroup carries adverse clinical weight. AR+/FOXA1+ TNBC has been associated with significantly worse recurrence-free and overall survival, higher risk of late recurrences, enrichment for PIK3CA mutations, and lower frequencies of BRCA1 promoter methylation, PTEN alterations, and PD-L1 expression than other TNBCs.
This is why FOXA1 needs careful framing on a TNBC page.
Low FOXA1 marks a more basal or stem-like, stress-tolerant state. Retained FOXA1 in AR+ TNBC marks a separate luminal-androgen-driven subtype with its own resistance pattern and poor long-term behavior.
3. FOXM1 — dominant proliferation and metastasis driver
FOXM1 is the heavier direct oncogenic driver in TNBC.
It is broadly upregulated in aggressive breast cancer and controls key steps in G1/S and G2/M progression, mitotic fidelity, spindle function, cyclin programs, and tumor growth.
Its effect is much broader than cell division alone.
FOXM1 promotes EMT, angiogenesis, invasion, metastasis, autophagy, stemness, and drug resistance, which is why it carries such high biologic weight in TNBC.
FOXM1 is linked to aggressive clinicopathologic features and poor prognosis in breast cancer, and the overlap between FOXM1 biology and classic TNBC behavior is especially strong.
On a TNBC page, FOXM1 should be presented as a central transcriptional command node rather than as an isolated proliferation marker.
4. What these pathways hit along the way
FOXA1 downstream consequences in TNBC
When FOXA1 is low, its loss derepresses SOD2 and IL6, increasing oxidative-stress tolerance, reducing apoptosis, increasing stem-like behavior, and promoting migration and malignancy.
This means FOXA1 loss supports TNBC progression through stress survival and inflammatory stemness programs rather than through a classic luminal receptor route.
FOXM1 downstream consequences in TNBC
FOXM1 affects multiple TNBC-relevant pathways and outputs.
Cyclin D1, cyclin A2, cyclin B, CDC25B, PLK1, Aurora kinase A, and centromere proteins, pushing cell-cycle progression and mitotic competence.
beta-catenin-linked invasion programs and MMP-2/MMP-9 activation, supporting extracellular matrix breakdown and migration.
VEGF transcription and angiogenesis, helping tumor expansion and dissemination.
PDGF-A/Akt signaling, reinforcing growth and tumorigenesis.
EMT regulators including Slug, plus TGF-beta/SMAD-linked metastatic transition programs.
LC3 and Beclin-1, supporting autophagy under stress.
Aurora kinase A-linked stem-cell programs, supporting tumorigenicity and self-renewal.
XIAP, survivin, DNA-repair programs, and spindle-associated pathways that support treatment resistance.
That pathway density is what gives FOXM1 its high functional weight in TNBC.
5. Honokiol and andrographolide in the FOXM1 framework
Honokiol — direct FOXM1 antagonist with broader survival-pathway effects
Honokiol directly binds and antagonizes FOXM1, suppressing FOXM1 protein levels and FOXM1-regulated target genes.
In breast cancer models, honokiol reduces FOXM1-driven transcription, causes cell-cycle arrest, and induces caspase-dependent apoptosis.
In TNBC, honokiol also inhibits several survival and invasion pathways that overlap with FOXM1 biology, including NF-kB, COX-2, PGE2, Src/EGFR, phospholipase D, Ras, and mTOR-linked signaling, while activating AMPK.
These effects map onto FOXM1-linked EMT, invasion, proliferation, and survival circuits, making honokiol relevant even in ER-negative disease.
Honokiol also matters across the broader breast cancer space because it inhibits growth of hormone-dependent and hormone-resistant breast cancer cells through NF-kB and Akt suppression and can weaken ER-linked survival circuitry while antagonizing FOXM1.
That gives honokiol dual FOXM1/ER-relevant action across subtypes, even though the ER piece is not the main reason it matters in TNBC.
Although honokiol’s best-established breast cancer role is direct FOXM1 antagonism, its known ability to suppress androgen receptor (AR) signalling in other hormone-driven cancers makes AR+/FOXA1+ luminal-like TNBC a particularly relevant context for further interest
Andrographolide — FOXM1-linked in ER+ disease and stemness-targeting in TNBC
In ER-positive breast cancer, andrographolide suppresses ESR1 transcription through a ROS-FOXM1 axis, reducing FOXM1 levels, decreasing ESR1 promoter activation, and lowering ER-alpha expression.
It also synergizes with fulvestrant in ER-positive models, making it relevant wherever FOXM1 helps maintain ER-driven survival.
In TNBC, andrographolide hits the disease from the stemness side.
It suppresses TNBC cancer stem-cell characteristics by downregulating THOC1 via NF-kB suppression and reduces mammosphere formation and tumor growth in experimental models.
This makes andrographolide relevant to a TNBC FOXM1 page even without a clean TNBC-specific FOXM1 paper for andrographolide, because it acts against overlapping upstream programs: stemness, survival under stress, and proliferative persistence.
6. Metastatic spread in TNBC
This is not a bone-only story.
FOXM1 is directly implicated in the steps required for broad metastatic spread, including EMT, invasion, angiogenesis, extracellular matrix remodeling, transport, colonization, and secondary growth.
That makes FOXM1 relevant to lung, liver, brain, and bone involvement rather than to one organ pattern alone.
FOXA1 affects spread more indirectly but still meaningfully. Loss of FOXA1 increases IL6- and SOD2-linked stemness, migration, stress tolerance, and invasive capacity, all of which are upstream features required for distant colonization.
In AR+/FOXA1+ TNBC, FOXA1 instead supports a luminal-like AR-driven proliferative program associated with late recurrence, suggesting a distinct timing and biology of metastatic risk within TNBC rather than a uniform metastatic pattern.
7. Treatment implications
FOXM1 is the more practical intervention node in TNBC because so many aggressive programs converge there.
Reported FOXM1-linked strategies in breast cancer include thiostrepton, FDI-6, honokiol, imipramine blue, panepoxydone, maslinic acid, and aptamer-based approaches, with effects that include suppression of cyclin programs, EMT regulators, metastasis pathways, and treatment resistance mechanisms.
FOXA1 is less straightforward to target because its role splits by subtype context.
In FOXA1-low TNBC, the issue is loss of suppression over SOD2, IL6, and stem-like aggressive behavior.
In AR+/FOXA1+ luminal-like TNBC, FOXA1 marks a subgroup where AR-directed strategies and PI3K-pathway considerations may matter more because of PIK3CA enrichment.
8. Summary
FOXM1 is one of the main master switches that makes TNBC fast-growing, aggressive, and more likely to spread.
It helps cancer cells divide, move, survive treatment, and keep stem-like cells alive.
FOXA1 is different.
In most TNBC it is too low, and that loss removes a brake on stress survival and stem-like behavior.
In one special AR-positive TNBC subgroup, FOXA1 stays active and helps drive a luminal-like growth pattern that is linked with worse long-term relapse risk.
Honokiol and andrographolide are relevant because they hit parts of this same control network.
References
FOXM1 in breast cancer and TNBC
FOXA1 in TNBC and AR+/FOXA1+ subgroup
Honokiol and FOXM1 or survival pathways
Andrographolide in ER+ and TNBC
Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
Last updated
Was this helpful?